DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT05701917

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
  • Inari Medical Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05701917
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Austria, Finland, Germany, Switzerland, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05701917. Randomized; no masking; primary purpose treatment. Start 2023-01-06 (actual); primary completion 2028-01-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
Acronym
DEFIANCE
Condition
Venous Thromboembolism
Condition
Deep Venous Thrombosis
Condition
Post-Thrombotic Syndrome
Intervention (Device)
ClotTriever System
Intervention (Drug)
Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.
Lead sponsor
Inari Medical (class: industry)

Record details

Record id
cardio:ct-nct05701917
Content hash
ea47123c1e7c61e504672c8352dcffcf33c28adffda0deec0c72d57bc33bd7df